Roche’s Tecentriq in combination with Abraxane improves outcomes as an initial treatment for people with PD-L1-positive metastatic triple-negative breast cancer.
Roche has announced positive results from the Phase III IMpassion130 study of Tecentriq® (atezolizumab) plus chemotherapy (Abraxane® [albumin-bound paclitaxel; nab-paclitaxel]) for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
Breast cancer is the most common cancer among women with more than 2 million diagnosed worldwide each year. TNBC represents approximately 15% of all breast cancers and is more common in women under the age of 50, compared with other forms of breast cancer. It is defined by the lack of expression and/or amplification of the targetable receptors for oestrogen, progesterone and HER2 amplification. Patients with metastatic TNBC generally experience rapid progression and shorter OS compared to other subtypes of breast cancer.
Tecentriq in combination with Abraxane significantly reduced the risk of disease worsening or death (progression-free survival; PFS) compared with chemotherapy alone in all randomised patients and the PD-L1-positive population, a subgroup determined by PD-L1 biomarker testing.
At this interim analysis, statistical significance was not met for overall survival (OS) in the ITT population, but showed a clinically meaningful 9.5-month OS improvement in the PD-L1-positive population. Due to the hierarchical statistical design, results in the PD- L1-positive population were not formally tested.
Follow-up will continue until the next planned analysis. Safety in the Tecentriq plus nab-paclitaxel arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination.
Currently, Roche has seven ongoing Phase III studies investigating Tecentriq in TNBC, including early and advanced stages of the disease.
Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the activation of T cells. Tecentriq has the potential to be used as a foundational combination partner with cancer immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers.
Tecentriq is already approved in the European Union, United States and more than 80 countries for people with previously treated metastatic non-small cell lung cancer (NSCLC) and for certain types of untreated or previously treated metastatic urothelial carcinoma (mUC).
Sandra Horning, MD, Roche?s Chief Medical Officer and Head of Global Product Development commented on the Tecentriq in combination with Abraxane trial, “These important results in people with metastatic triple-negative breast cancer whose disease expresses the PD-L1 protein are highly encouraging and represent a significant step forward in the treatment of this challenging disease. We have shared the IMpassion130 results with global health authorities with the hope of bringing this Tecentriq in combination with Abraxane to people with PD-L1- positive, metastatic triple-negative breast cancer as soon as possible.”